Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KLK8 | O60259 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | KLK2 | P20151 | 2/20 | 0.43 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945259 | 0.84 | SRC (0.54) | SRCBTN3A1L3MBTL1TDP1KLK8 | |
| SCHEMBL28761532 | 0.83 | SRC (0.53) | SRCL3MBTL1TDP1ALDH1A1ANPEP | |
| SCHEMBL2980549 | 0.81 | BTN3A1 (0.49) | SRCBTN3A1L3MBTL1TDP1KLK8 | |
| SCHEMBL2720079 | 0.81 | POLB (0.59) | SRCBTN3A1L3MBTL1TDP1 | |
| SCHEMBL2154812 | 0.80 | SMN1; SMN2 (0.49) | SRCBTN3A1L3MBTL1TDP1KLK8 | |
| SCHEMBL3626452 | 0.80 | L3MBTL1 (0.42) | SRCBTN3A1L3MBTL1TDP1KLK8 | |
| SCHEMBL9377254 | 0.79 | SRC (0.48) | SRCBTN3A1L3MBTL1TDP1KLK8 | |
| SCHEMBL1450572 | 0.79 | LMNA (0.48) | SRCBTN3A1L3MBTL1ALDH1A1 | |
| SCHEMBL28916176 | 0.78 | SRC (0.47) | SRCL3MBTL1TDP1 | |
| SCHEMBL1905315 | 0.78 | ALDH1A1 (0.44) | SRCBTN3A1L3MBTL1TDP1KLK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296933-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-8962192-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| CN-102780038-A | Nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20100035147-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| CN-101622751-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2010-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296933-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11B1, CYP11A1, CYP11B2 | SRC 2090/4885BTN3A1 4790/4885L3MBTL1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.